Verona Pharma Plc - ADR is a global clinical-stage biopharmaceutical company. The company is focused on developing and commercialising treatments for respiratory diseases.
Operating as part of the biotech industry, Verona Pharma Plc’s primary service is the development of drugs to counter respiratory diseases, specifically chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma. Its product candidate ensifentrine is being developed as an inhaled treatment for respiratory disease that combines anti-inflammatory and bronchodilator activity into one compound.
Stay up to date on the share price of VRNA by adding it to your eToro watchlist.